TechnologyNVIDIA's BioNeMo Locks In Thermo Fisher, Eli Lilly as Global Pharma Shifts to Shared AI PlatformsSalvado•Jul 9, 2026
Health & BiotechNovo Nordisk Surges 24.9%, Exits Parkinson's Unit as NVIDIA's BioNeMo Becomes Global Pharma AI StandardSalvado•Jun 27, 2026
Biotech & PharmaNovo Nordisk Exits Internal Parkinson's Research, Handing Discovery to AI Partner as NVIDIA's BioNeMo Becomes Global Pharma InfrastructureSalvado•Jun 25, 2026
Health & BiotechNVIDIA's BioNeMo Becomes Global Drug Discovery Infrastructure as Pharma Outsources R&D to AI PlatformsSalvado•Jun 19, 2026
Health & BiotechNVIDIA BioNeMo Becomes Global Pharma's AI Backbone as Novo Nordisk Outsources Parkinson's R&DSalvado•Jun 9, 2026
Health & BiotechNovo Nordisk Exits Cell Therapy, Hands Parkinson's Program to AI Startup as NVIDIA Locks In Global Pharma DealsSalvado•Jun 5, 2026
Technology & ScienceNVIDIA Locks Eli Lilly and Thermo Fisher Into AI Drug Discovery Platform as Pharma R&D Goes StructuralSalvado•Jun 1, 2026
Health & ScienceNVIDIA Locks Global Pharma Into AI Drug Discovery as Novo Nordisk Surges 24.9%Salvado•May 31, 2026
Technology & ScienceNVIDIA's BioNeMo Becomes Global Drug Discovery's Default AI Infrastructure as Big Pharma Cedes Biology to SpecialistsSalvado•May 21, 2026
Health & BiotechNVIDIA's BioNeMo Becomes Global Pharma Infrastructure as Novo Nordisk, Eli Lilly Rebuild R&D Around AISalvado•May 18, 2026
Health & ScienceNovo Nordisk Shares Surge 24.9% as Global Pharma Abandons Wet Labs for AISalvado•May 13, 2026
Healthcare & PharmaceuticalsPfizer Joins the Global Obesity Race: GLP-1 Market Entry Planned by 2028 Following Metsera AcquisitionViaNews Editorial Team•Feb 18, 2026
